Perspectives

Roberto Leone and Lara Magro
Focus Farmacovigilanza 2015;89(8):1
Earlier this year, at the presentation of the OsMed/AIFA report on drug consumption in Italy, health Minister Lorenzin expressed "grave concern at the increased consumption of opiates." Are Minister's concerns justified? Were we not the country with one of the lowest morphine consumption rates in...
Roberto Satolli
Focus Farmacovigilanza 2015;88(5):1
Last October, when I wrote an editorial for Focus Pharmacovigilance (Focus November-December 2014, page 1) about "Ebola exceptions" concerning the rules for assessing the safety and efficacy of drugs, I could never have imagined that within a few days I would find myself personally involved in the...
Giampaolo Velo, Mauro Venegoni, Pietro Dri
Focus Farmacovigilanza 2015;88(5):1
The bulletin “Focus Farmacovigilanza” has always been particularly sensitive to the conflict of interest issue, to the point of reporting to the reader even the possible conflicts concerning the sources used in the various articles. It’s worth reminding that “Focus Farmacovigilanza” is not a...
Fabio Firenzuoli
Focus Farmacovigilanza 2015;87(3):1
The term “herbal” often instinctively arouses an immediate sense of stiffened perplexity, caution, mistrust or complete opposition in pharmacologists as well as clinicians, not least of all because numerous active or non-active destabilising factors are present within in the same botanical species...
Monia Donati, Mauro Melis
Focus Farmacovigilanza 2015;86(1):1
"Can we rely on RE-LY?" was the title of an editorial in the New England Journal of Medicine1 in 2009, commenting on the RE-LY study2 which compared dabigatran (110 and 150 mg), the first member of the new class of oral anticoagulants, and warfarin in patients with non-valvular atrial fibrillation...
Roberto Satolli, Zadig
Focus Farmacovigilanza 2014;85(11):1
The tragedy of Ebola, in its now catastrophic development, besides wiping out so many human lives is already producing a cascade of effects at a global level whose extension and broad reach are impossible to foresee.Also drug safety evaluation (or, as it is always better to say, the benefit-damage...
Alasdair Breckenridge
Focus Farmacovigilanza 2014;84(5):1
When a medicine is marketed, much is known about its quality and pharmacology and in its efficacy in a carefully screened group of patients in clinical trials. These data, however, may provide an incomplete and even misleading account of the drug’s effectiveness in the community at large. Even less...
Ivor Ralph Edwards
Focus Farmacovigilanza 2014;83(7):1
In FOCUS March 2013, Antonio Addis discusses the inadequacies of information and communication in pharmacovigilance and also challenges us, ‘Do try and find someone asserting that information in pharmacovigilance is useless’. In FOCUS July 2013, Richard Smith talks about peoples’ perception of drug...
Giovanni Serpelloni1 and Claudia Rimondo2
Focus Farmacovigilanza 2014;82(5):1
New psychoactive substances (NPS) and their commercialization on the Internet In the last years the United Nations and the European Union have often reported the appearance, on the illegal drug market, of new psychoactive substances (NPS), purely synthetic and characterized by particularly harmful...
Pier Mannuccio Mannucci
Focus Farmacovigilanza 2014;81(3):1
More than two thirds of people undergoing long-term anticoagulant therapy with the vitamin-K antagonists (VKAs) warfarin and acenocoumarol have non–valvular atrial fibrillation (AF). This cardiac arrhythmia affects as many as 8.8 million people in the European Union, 700.000 in Italy. Because AF...

Pages